By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:




Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Another Healthcare Provider Accuses Genentech (RHHBY) of Fudging the Amount of Herceptin in Each Vial 5/23/2016 7:09:25 AM
Phase III Study Of Genentech (RHHBY)’s Alecensa (Alectinib) Showed Superior Efficacy Versus Crizotinib In Japanese People With A Specific Type Of Lung Cancer 5/19/2016 7:30:52 AM
Genentech (RHHBY) Nabs FDA Approval of First New Bladder Cancer Drug in 30 Years 5/18/2016 12:20:09 PM
Genentech (RHHBY) May Owe Refunds to Some Healthcare Providers Over 340B Price Violations 5/12/2016 7:40:30 AM
Stand Up To Cancer And Genentech (RHHBY) Join Forces Through "Be The Breakthrough" Campaign 5/4/2016 9:18:30 AM
Genentech (RHHBY) Highlights Personalized Medicines And Cancer Immunotherapies At 2016 ASCO Annual Meeting 5/3/2016 11:05:44 AM
Astex Pharma (ASTX) and Genentech (RHHBY) Forge a Clinical Trial Deal for Acute Myeloid Leukemia 4/20/2016 6:55:53 AM
Genentech (RHHBY) To Present New Data At American Academy of Neurology Showing Superior Efficacy Of Investigational Medicine Ocrelizumab Versus Comparators On Disease Activity And Progression In Two Forms Of Multiple Sclerosis 4/13/2016 10:46:43 AM
Genentech (RHHBY) Announces FDA Grants Venclexta (Venetoclax) Accelerated Approval For People With A Hard-To-Treat Type Of Chronic Lymphocytic Leukemia 4/12/2016 11:13:56 AM
FDA Green Lights AbbVie (ABBV), Genentech (RHHBY)'s New Chronic Lymphocytic Leukemia Drug Venclexta 4/11/2016 11:42:11 AM